NRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) denied the Breakthrough Therapy designation (BTD) request for ZYESAMI® (aviptadil) and emphasized its focus on the company's NRX-101 BTD compound for Bipolar Depression associated with Suicidality. The request for BTD was submitted based on the positive finding of a post-hoc subgroup analysis of patients who in addition to Aviptadil or placebo were also treated with Remdesivir and whose respiratory failure due to Critical COVID-19 continued to progress.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | -8.17% | +8.91% | -38.91% |
05-06 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
05-06 | NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.91% | 31.89M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- NRXP Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI®